18F-FDG-PET/MRI in lymphoma patients

被引:14
作者
Ferdova, Eva [1 ]
Ferda, Jiri [1 ]
Baxa, Jan [1 ]
机构
[1] Univ Hosp Plzen, Clin Imaging Methods, Alej Svobody 80, Plzen 30460, Czech Republic
关键词
PET/MRI; Hybrid imaging; Lymphoma; Deauville score; Fluorodeoxyglucose; B-CELL LYMPHOMA; PROGNOSTIC VALUE; FDG-PET; DIAGNOSTIC PERFORMANCE; FOLLICULAR LYMPHOMA; PEDIATRIC LYMPHOMA; HODGKINS LYMPHOMA; PROGRESSION-FREE; INTERIM; PET/MRI;
D O I
10.1016/j.ejrad.2017.01.023
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The introduction of hybrid PET/MRI imaging using integrated systems into clinical practice has opened up the possibility of reducing the radiation dose from hybrid imaging by eliminating the contribution from computed tomography. Studies comparing the possibilities of PET/CT and PET/MRI imaging demonstrated it is possible to use the advantages of the high contrast resolution of magnetic resonance for soft tissue and bone marrow along with PET records in a quality comparable to PET/CT imaging. The significant feature for PET imaging in Hodgkinis lymphoma is that it is a tissue with high levels of radiopharmaceutical accumulation, which decreases proportionally after successful therapeutic effect, the effect of therapy is assessed using Deauville score system on interim examinations. While the efficacy of prognosis determined using the Deauville scale in HL is widely accepted, it turns out that in DLBCL, the prognostic value of PET imaging is bound to the evaluation of subtypes. PET/MRI scanning can be used to evaluate a relapse if follicular lymphoma has already been treated, or to confirm transformation into more aggressive forms. In children and adults with Burkitt's lymphoma, negative findings after induction therapy have a high negative predictive value for relapse prognosis. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:A52 / A63
页数:12
相关论文
共 24 条
[1]  
Adams H. J., 2016, ANN HEMATOL, V3
[2]  
Adams H. J., 2016, NUCL MED COMMUN, V5
[3]   Seriously overestimated prognostic value of baseline and interim FDG-PET in diffuse large B cell lymphoma [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
ANNALS OF HEMATOLOGY, 2016, 95 (08) :1367-1368
[4]   Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review [J].
Adams, Hugo J. A. ;
Nievelstein, Rutger A. J. ;
Kwee, Thomas C. .
ANNALS OF HEMATOLOGY, 2016, 95 (01) :11-18
[5]  
Afaq A., 2016, CLIN NUCL MED, V7
[6]  
Albano D., 2016, J MAGN RESON IMAGING, V7
[7]  
Annunziata S., 2016, ANN NUCL MED, V31
[8]   Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients [J].
Atkinson, Wendy ;
Catana, Ciprian ;
Abramson, Jeremy S. ;
Arabasz, Grae ;
McDermott, Shanaugh ;
Catalano, Onofrio ;
Muse, Victorine ;
Blake, Michael A. ;
Barnes, Jeffrey ;
Shelly, Martin ;
Hochberg, Ephraim ;
Rosen, Bruce R. ;
Guimaraes, Alexander R. .
ABDOMINAL RADIOLOGY, 2016, 41 (07) :1338-1348
[9]   Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma [J].
Buchbender, Christian ;
Heusner, Till A. ;
Lauenstein, Thomas C. ;
Bockisch, Andreas ;
Antoch, Gerald .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (08) :1244-1252
[10]   Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era [J].
Costa, Renata de Oliveira ;
Hallack Neto, Abrahao ;
Siqueira, Sheila ;
de Padua Covas Lage, Luis Alberto ;
de Paula, Henrique M. ;
Coutinho, Arthur M. ;
Pereira, Juliana .
NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (10) :1095-1101